Accessibility Menu
Xilio Therapeutics logo

Xilio Therapeutics(NASDAQ) XLO

Market Cap$60.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-96%
5 YearN/A
1 Year-0%
1 Month-1%
$9.19
-0.86%
-0.08Today
Xilio Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 9.172026-08-07
Xilio Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.66%USD 9.112026-07-31
1 month-1.19%USD 9.282026-07-08
3 month+18.48%USD 7.742026-05-08
Year to date+2.31%USD 8.962025-12-31
1 year-0.06%USD 9.182025-08-07
3 year-76.27%USD 38.642023-08-08
Since inception-95.91%USD 224.002021-10-22

Xilio Therapeutics Financials at a Glance

Market Cap

$60.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$53.48M

Net Income (TTM)

-$31.30M

EPS (TTM)

-$3.66

P/E Ratio

-2.51

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$9.19

Volume

11,519

Open

$9.40

Previous Close

$9.17

Daily Range

$8.88 - $9.40

52-Week Range

$6.47 - $12.74

Estimated Earnings Date

Aug 13, 2026

XLO News

Foolcom-Featured.png

Xilio Revenue Jumps 246 Percent in Q2

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Xilio Therapeutics

Xilio develops medicines that help the immune system fight cancer. Its therapies aim to target tumors while reducing side effects. These treatments are designed for people with solid tumors who need new options.

Lab Bench to Bedside: What Xilio Sells

  • Checkpoint Inhibitor Program: XTX101, a therapy that helps the immune system attack cancer cells; 100% of revenue comes from partnerships, not product sales.
  • Cytokine Programs: Includes XTX301 (IL-12) and XTX401 (IL-15), which are designed to boost immune response in tumors; XTX202 (IL-2) is discontinued.
  • Bispecific and Multi-specific Programs: Early-stage therapies that combine two or more immune targets, aiming to improve cancer treatment precision.
  • Strategic Collaborations: Revenue comes from research partnerships with large pharmaceutical companies, not from direct product sales.

Growth Spurts and Strategic Moves

  • Signed a collaboration with AbbVie in February 2025 for up to four immuno-oncology programs.
  • Entered an exclusive license with Gilead in March 2024 for its IL-12 program.
  • Advanced XTX501 and multi-specific T cell engager programs into preclinical development in 2025-2026.
  • Reduced workforce by 21% in March 2024 to focus on core programs.
  • Raised new capital through follow-on offerings in June 2025 and February 2026.

Why Xilio Stands Out (Without the Lab Coat)

Xilio uses a masking technology that activates drugs only inside tumors, aiming to reduce side effects. The company relies on partnerships for funding and development, not product sales. Its intellectual property portfolio covers multiple drug candidates and technologies.

Five Things You Need to Know

  • Revenue was $19 million in Q3 2025, up 742.5% from Q3 2024.
  • Net loss was $2 million in Q3 2025, improved 86.9% from Q3 2024.
  • Cash and cash equivalents were $137.5 million as of December 31, 2025.
  • All revenue comes from collaboration and license agreements, not product sales.
  • Operating expenses rose to $85.7 million in 2025, up 28% from 2024.

Bottom Line

Xilio has shifted from early research to clinical partnerships, focusing on immune-based cancer therapies. The company depends on collaborations and milestone payments for its financial health.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

76

CEO

René Russo, PharmD

Website

www.xiliotx.com

Headquarters

Waltham, MA 02451, US

XLO Financials

Key Financial Metrics (TTM)

Gross Margin

70.69%

Operating Margin

-78.98%

Net Income Margin

-58.52%

Return on Equity

-117.24%

Return on Capital

-99.42%

Return on Assets

-19.15%

Earnings Yield

-39.84%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$60.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.58M

Volume

11.52K

Avg. Volume

47.61K

Financials (TTM)

Gross Profit

$37.81M

Operating Income

-$42.24M

EBITDA

-$29.91M

Operating Cash Flow

-$56.31M

Capital Expenditure

-$1.05M

Free Cash Flow

-$57.37M

Cash & ST Invst.

$150.33M

Total Debt

$6.64M

Xilio Therapeutics Performance Analysis

Xilio Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 6,344,000N/A
20252025-12-31USD 43,766,000589.9%
Xilio Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30175.9%
Q32025-09-30135.8%
Q42025-12-31-28.2%
Q12026-03-31-7.6%
Xilio Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -45.0916.2%
20232023-12-31USD -38.90-13.7%
20242024-12-31USD -15.24-60.8%
20252025-12-31USD -4.19-72.5%
Xilio Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-72.2%
Q32025-09-3064.5%
Q42025-12-31152.6%
Q12026-03-31-171.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$12.65M

+331.7%

Gross Profit

$12.30M

+319.9%

Gross Margin

97.28%

N/A

Market Cap

$60.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$793.34K

N/A

Employees

76

N/A

Net Income

-$9.53M

+28.2%

EBITDA

-$9.19M

+28.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$150.33M

+68.8%

Total Debt

$6.64M

-15.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$5.25M

-20.8%

Short Term Debt

$1.38M

+12.9%

Return on Assets

-19.15%

N/A

Return on Invested Capital

-35.05%

N/A

Free Cash Flow

-$22.90M

-179.1%

Operating Cash Flow

-$22.34M

-177.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OKUROnKure Therapeutics, Inc.
$4.14-0.24%
KZRKezar Life Sciences, Inc.
$7.29+0.00%
LVTXLAVA Therapeutics N.V.
$1.74-3.87%
PDSBPDS Biotechnology Corporation
$0.78+3.77%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About XLO

What is the current price of Xilio Therapeutics?

Xilio Therapeutics is trading at $9.17 per share.

What is the 52-week range for Xilio Therapeutics?

Over the past 52 weeks, Xilio Therapeutics has traded between $6.47 and $12.74.

How much debt does Xilio Therapeutics have?

As of the most recent reporting period, Xilio Therapeutics reported total debt of $6.64M.

How much cash does Xilio Therapeutics have on hand?

Xilio Therapeutics reported $150.33M in cash and cash equivalents in its most recent financial results.

What is Xilio Therapeutics’s dividend yield?

Xilio Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services